Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01496053

Enrollment

100

Registered

2011-12-21

Start date

2011-12-31

Completion date

2016-01-31

Last updated

2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis

Keywords

Cytokine levels in blood, Calprotectin in feces, Clinical symptom score.

Brief summary

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease. A prospective randomised study comparing the mushroom extract with placebo.

Interventions

DIETARY_SUPPLEMENTAndoSan

AndoSan 30 ml x 2 for 21 days

DIETARY_SUPPLEMENTSugar Extract

Sham comparator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* moderate disease

Exclusion criteria

* serious disease, * biological treatment, * pregnancy.

Design outcomes

Primary

Measure	Time frame
Reduction in biochemical blood parameters (pro-inflammatory cytokines)	21 days

Secondary

Measure	Time frame
Reduction of calprotectin in feces.	21 days
Clinical symptom score.	21 days

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026